By A Mystery Man Writer
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel educational camp
Digital health news, funding round up in the prior week; November 21, 2022
Endpoints News — Genentech touts Tecentriq combo data in liver cancer; Rep. Frank Pallone criticizes noncompliance with trial records law
ICS 2022 Abstract #6 Efficacy and Safety of a Novel Gene Therapy (URO-902; pVAX/hSlo) in Female Patients With Overactive Bladder Syndrome and Urgency Urinary Incontinence: Results From a Phase 2a Trial
Vibrant America Total Tox Burden -Urine Sample – Dr Jaban Moore - Store
Overactive Bladder Urology - Top Urologist NYC
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health
Translating Policy into Practice: Sexual Violence Policies and the University
Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season
EHR vendors don't have to draw a 'line in the sand' on reproductive data privacy
Bill banning puberty blockers, hormone treatments for trans kids sent to Texas governor
Welcome to Urovant Sciences Medical Affairs
Contact Us Battle River Treaty 6 Health Centre